Skip to main content
Figure 2 | Clinical Epigenetics

Figure 2

From: Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

Figure 2

Pharmacokinetics of 5-AZA-CdR at a dose of 15 mg/m2as a three-hour i.v. infusion to patients with AML and MDS [[92]]. After i.v. infusion of 5-AZA-CdR, it reaches a steady-state plasma level within two hours, confirming its very short half-life. 5-AZA-CdR, 5-aza-2′-deoxycytidine; AML, acute myeloid leukemia; i.v., intravenous; MDS, myelodysplastic syndrome.

Back to article page